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Abstract
Genetic evidence implicates the loss of bone morphogenetic protein type II receptor (BMPR-II) 
signaling in the endothelium as an initiating factor in pulmonary arterial hypertension (PAH). 
However, selective targeting of this signaling pathway using BMP ligands has not yet been 
explored as a therapeutic strategy. We identified BMP9 as the preferred ligand for preventing 
apoptosis and enhancing monolayer integrity in both pulmonary arterial endothelial cells and 
blood outgrowth endothelial cells from subjects with PAH bearing mutations in BMPR-II. In vivo, 
we report the spontaneous generation of PAH in a mouse model bearing a heterozygous knock-in 
of a human BMPR-II mutation, R899X. Administration of BMP9 reversed established PAH in 
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Bmpr2+/R899X mice, as well as in models of disease developed in response to either monocrotaline 
or VEGF receptor inhibition combined with chronic hypoxia. These results demonstrate the 
promise of direct enhancement of endothelial BMP signaling as a novel therapeutic strategy for 
PAH.
Heritable and idiopathic pulmonary arterial hypertension (PAH) are characterized by 
narrowing and obliteration of precapillary pulmonary arteries, secondary to proliferation and 
apoptosis resistance of endothelial cells, smooth muscle cells, and fibroblasts1. The resulting 
increase in pulmonary vascular resistance causes severe elevation of pulmonary artery 
pressure, leading to right ventricular hypertrophy and ultimately death from right heart 
failure2. The identification of heterozygous germline mutations in the gene encoding the 
bone morphogenetic protein type II receptor (BMPR-II) in 20003,4 provided major insights 
into the pathobiology of heritable PAH. Subsequent studies also identified BMPR-II 
mutations in 15–40% of idiopathic PAH cases5, and found that reduced BMPR-II expression 
is a feature of non-genetic forms of PAH in humans6 and animal models7.
Genetic evidence strongly implicates the endothelial cell as the key initiating cell type in 
PAH. Previous studies showed that conditional deletion of BMPR-II in the endothelium is 
sufficient to induce PAH in a proportion of mice8 and that rescue of endothelial BMPR-II 
expression reverses experimental pulmonary hypertension9–11. In addition, mutations in the 
type I receptor, ALK-112, and the type I receptor accessory protein, endoglin13, are found in 
individuals with PAH, both of which are almost exclusively expressed on the endothelium. 
Despite this evidence, the precise nature of the endothelial dysfunction in the pathobiology 
of PAH and the involvement of BMP signaling in this process remain uncertain. Although 
established PAH is characterized by the excessive clonal proliferation of pulmonary 
endothelial cells14 as a component of obstructive cellular lesions, the initiation of disease 
pathology15,16,17 has been linked to a paradoxical increase in endothelial cell apoptosis. 
Additional studies have identified a role for endothelial BMPR-II loss in the exacerbation of 
vascular permeability and the altered translocation of leukocytes across the vascular 
wall18–20.
While in vitro studies using pulmonary artery smooth muscle cells (PASMCs) demonstrated 
that increasing concentrations of BMP ligand overcomes the loss of function associated with 
mutations in the BMP signaling pathway21, to date, no study has therapeutically delivered 
BMP ligand in vivo to provide proof-of-concept for such an approach in the treatment of 
PAH. The complexity of the BMP receptor family, which is comprised of four type-II 
receptors, five type-I receptors and over twenty BMP ligands22, may account for the absence 
of such studies. Identifying an appropriate ligand to selectively target the pulmonary 
endothelium presents a significant challenge. Recently, BMPR-II was found to form a 
signaling complex with ALK-1 and signal specifically in response to BMP9 and 10 in 
microvascular endothelial cells23. Unlike other BMPs, BMP9 circulates at measureable 
concentrations in serum and is thought to act as a vascular quiescence factor, blocking 
angiogenesis in vitro24 and in vivo25, making it a candidate for therapeutically targeting the 
dysfunctional pulmonary endothelium.
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Here we examined the therapeutic administration of BMP9 to prevent and reverse 
established PAH by selectively enhancing endothelial BMPR-II signaling. BMP9 acts 
directly on the endothelium to promote vascular stability by preventing both apoptosis and 
angiogenesis, and by promoting monolayer integrity. We also report a novel mouse model of 
PAH, bearing a constitutive knock-in of a common human disease causing mutation at 
amino acid 899 (R899X) of the endogenous Bmpr2 locus. Unlike previous mouse models of 
somatic BMPR-II haploinsufficiency26,27, mice heterozygous for this knock-in 
(Bmpr2+/R899X) spontaneously develop pulmonary hypertension. The therapeutic delivery of 
BMP9 effectively prevents and reverses established pulmonary hypertension in both the 
knock-in model and the monocrotaline and sugen-hypoxia models of PAH. Together, these 
studies underscore a role for BMP9 as a vascular stability and quiescence factor and provide 
a translational framework for the delivery of this BMP ligand as a treatment strategy for 
PAH.
Results
BMP9 elicits endothelial-selective transcriptional regulation
We sought to identify a BMP ligand for therapeutic delivery that would selectively and 
efficiently enhance canonical BMP signaling in the endothelium while minimizing the 
potential for deleterious off-target effects, such as the calcification of soft tissue28. As an 
initial screen, we stimulated human pulmonary arterial endothelial cells (PAECs) with 
BMP9, BMP2 or BMP6 and assessed changes in gene transcription by microarray. Unlike 
BMP2 and BMP6, which induced negligible gene expression, BMP9 induced the differential 
regulation of 1883 genes (adjusted P value < 0.05), including several key components of 
canonical BMP signaling such as ID1, ID2 and BMPR2 (Fig. 1a–c). Generally applicable 
gene-set enrichment (GAGE) analysis for common signaling pathways and cellular 
processes revealed TGF-β signaling as the only pathway to be significantly (P=0.0012) 
upregulated by BMP9. However, BMP9 also downregulated other pathways, including 
apoptotic cell signaling (Fig. 1d; Supplementary Fig. 1). Signaling pathway impact analysis 
(SPIA) of common signaling pathways confirmed the TGF-β pathway as the only pathway 
to be enhanced in response to BMP9 treatment, supporting a central role for the canonical 
Smad pathway in the actions of BMP9 (Fig. 1e). We obtained similar results using blood 
outgrowth endothelial cells (BOECs) from healthy subjects, which, like PAECs, responded 
almost exclusively to BMP9 stimulation (Supplementary Fig. 2). Analysis of BMP9-induced 
gene expression for specific members of the TGF-β pathway revealed an enhancement of 
classical downstream targets of BMP signaling, whereas expression levels of TGF-β1 
downstream targets, including PAI-1, Myc and CTGF, remained unchanged (Supplementary 
Fig. 3a). Of note, BMP9 did not alter the expression of a selected group of endothelial-
derived paracrine factors and typical PASMC mitogens, including members of the PDGF 
and FGF families of cytokines (Supplementary Fig. 3b).
Validation of BMP responsiveness in PAECs by immunoblotting confirmed robust 
induction of Smad1/5/8 phosphorylation, ID1 and ID3 in PAECs in response to BMP9 
concentrations as low as 0.1 ng/mL. In contrast, other BMPs were much less effective over 
the range of doses tested (Fig. 1f, Supplementary Fig. 4b). As a further measure of 
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endothelial selectivity, PASMCs displayed a modest response to BMP9 when compared to 
an equivalent dose range of other BMPs (Supplementary Fig. 4a, b). We observed similar 
responses in additional endothelial cell lines (Supplementary Fig. 4b). As a further measure 
of the endothelial selectivity of BMP9 in the pulmonary circulation, we stimulated freshly 
isolated rat pulmonary arteries ex vivo with BMP9 and assessed for induction of Smad1/5 
phosphorylation. We observed phospho-Smad immunostaining exclusively in the 
endothelium, with no measurable signal in the underlying smooth muscle (Supplementary 
Fig. 4c).
The array study also identified a notable capacity of BMP9 to induce BMPR2 gene 
expression, which was validated by immunoblotting and qPCR (Fig. 1f–g). siRNA 
knockdown of Smad1, with or without Smad5 knockdown, eliminated the capacity of BMP9 
to enhance BMPR2 expression (Supplementary Fig. 5a–d), supporting the importance of 
canonical Smad signaling to this process. To confirm this finding, we identified a putative 
Smad binding site on the BMPR2 promoter (Supplementary Fig. 5e) and used chromatin 
immunoprecipitation in human microvascular endothelial cells (HMEC-1) to demonstrate p-
Smad1/5 and Smad4 binding to this region, which was lost following siRNA knockdown of 
Smad1 and enhanced in response to treatment with BMP9 (Fig. 1h). HMEC-1 cells 
transfected with a luciferase reporter construct downstream of a 5kb segment of the BMPR2 
promoter exhibited enhanced basal luciferase activity versus a control vector without the 
BMPR2 promoter region, which was further elevated in response to BMP9 treatment (Fig. 
1i). Mutation of the putative Smad binding region in the 5kb segment reduced both baseline 
luciferase activity and BMP9 regulation of the promoter. We did not observe a similar 
enhancement of BMPR2 expression in PASMCs in response to treatment with BMP9, BMP2 
or BMP6 (Supplementary Fig. 5f).
BMP9 prevents endothelial cell apoptosis and permeability
As reported previously29, PAECs stimulated with TNFα in the presence of cyclohexamide 
exhibited elevated JNK phosphorylation as a part of an apoptotic signaling cascade (Fig. 2a). 
Pre-treatment of PAECs with BMP9 prevented JNK phosphorylation and blocked the 
induction of apoptosis, as demonstrated by immunoblotting for cleaved caspase-3 (Fig. 2b) 
and by flow cytometry for early apoptotic, Annexin-V+/PI− cells (Fig. 2c, d). Since BMP9 
signals via complexes of the type I receptor ALK1 with either BMPR-II or ActR-II as the 
type II receptor30, we determined whether the anti-apoptotic effects of BMP9 were indeed 
BMPR-II dependent. siRNA knockdown of BMPR-II (Fig. 2e) eliminated the capacity of 
BMP9 to prevent apoptosis when compared to controls (Fig. 2f, g). Importantly, siRNA 
knockdown of Smad1 and Smad5 also partially blocked the anti-apoptotic effect of BMP9, 
reinforcing the importance of canonical Smad signaling in this process (Supplementary Fig. 
6).
BOECs from healthy controls and individuals with PAH-associated mutations in BMPR2 
were used as a surrogate for PAECs to determine the efficacy of BMP9 therapy in the 
context of BMPR2 mutations. Although mutation-bearing BOECs displayed an increased 
susceptibility to apoptosis when compared to cells isolated from healthy control subjects 
(Fig. 3a), BMP9 blocked JNK phosphorylation (Fig. 3b) and apoptosis in both control and 
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mutation-bearing BOECs (Fig. 3a, c), supporting the benefit of this approach, even in the 
context of BMPR-II deficiency.
We also examined the effect of BMP9 on endothelial barrier integrity (Fig. 3d–g). LPS 
stimulation of control BOECs resulted in increased monolayer permeability that was 
blocked by the addition of BMP9. BOECs with BMPR2 mutations demonstrated greater 
permeability in response to LPS. However, as with the apoptotic responses, heterozygous 
BMPR2 mutation in these cells did not prevent the capacity of BMP9 to block LPS-induced 
monolayer permeability. BMP9 also reduced the basal permeability of unstimulated, 
mutation bearing BOECs (Fig. 3f). We observed similar results in PAECs in response to 
TNFα or thrombin-induced permeability (Supplementary Fig. 7a). VE-cadherin staining 
demonstrated impaired cell-cell junctions in response to all three stimuli that was blocked by 
BMP9 (Fig. 3g, Supplementary Fig. 7b).
Bmpr2+/R899X mice develop age-related pulmonary hypertension
In order to determine whether exogenous administration of BMP9 would be beneficial in a 
mouse model of PAH that mimics the genetics of human disease, we created a knock-in 
mouse, bearing the human disease-associated R899X premature stop mutation in exon 12 of 
the endogenous Bmpr2 locus (Supplementary Fig. 8a). As reported for Bmpr2 null mice31, 
mice homozygous for the R899X mutation were non-viable. Heterozygous Bmpr2+/R899X 
mice developed normally and displayed reduced BMPR-II protein (Supplementary Fig. 8b) 
and mRNA (Supplementary Fig. 8c), consistent with an R899X mutation that leads to 
mRNA degradation by nonsense mediated mRNA decay (NMD) in humans32. We 
confirmed NMD of the R899X transcript in both mouse and human smooth muscle cells 
bearing the mutant allele (Supplementary Fig. 8d–i). Bmpr2+/R899X mice exhibited normal 
right ventricular systolic pressures (RVSP) at 3 months of age (Supplementary Fig. 9a), but 
developed elevated RVSP by 6 months (Fig. 4a). While this increase in RVSP was not 
accompanied by right ventricular hypertrophy (Fig. 4b), 6 month-old Bmpr2+/R899X mice did 
exhibit enhanced muscularization of peripheral pulmonary arteries in the lung (Fig. 4c, d). 
Further characterization of left ventricular function demonstrated no significant differences 
in left ventricular end diastolic pressure or cardiac output between 6 month-old 
Bmpr2+/R899X and WT controls (Supplementary Table 1). In contrast, 6 month-old 
Bmpr2+/− mice did not exhibit elevated RVSP or RV hypertrophy in our hands 
(Supplementary Fig. 9e–f).
To examine the importance of canonical Smad signaling in this PAH model, we also 
assessed the pulmonary vascular phenotype of mice heterozygous for Smad133. Male 
Smad1+/− mice did not exhibit raised RVSP or RV hypertrophy at 3 or 6 months (Fig. 4e, f; 
Supplementary Fig. 9b–d). However, the generation of Bmpr2+/R899X/Smad1+/− compound 
heterozygotes resulted in mice that, by 6 months, developed more severe elevations in RVSP 
than those heterozygous for R899X alone (Fig. 4e). Unlike Bmpr2+/R899X mice, this more 
pronounced elevation in RVSP was also accompanied by right ventricular hypertrophy in 
Bmpr2+/R899X/Smad1+/− mice when compared to WT controls (Fig. 4F). Both 
Bmpr2+/R899X and Bmpr2+/R899X/Smad1+/− compound heterozygous mice exhibited 
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reduced BMPR-II protein and pulmonary Smad1/5 phosphorylation compared to WT 
littermate controls (Supplementary Fig. 9e–g).
BMP9 reverses pulmonary hypertension in Bmpr2+/R899X mice
Treatment of 6 month-old Bmpr2+/R899X mice with BMP9 (75 ng daily, i.p.) for 4 weeks 
reversed all indices of PAH in this chronic disease model, returning RVSP to the level seen 
in WT mice (Fig. 4a) and reversing the enhanced pulmonary arterial muscularization in 
these mice (Fig. 4c, d). The dose selection was based on an initial, 7-day chronic dose-
ranging study in rats (Supplementary Fig. 10a) and translated to mice on a weight/weight 
basis (Supplementary Fig. 10b).
We also used pulmonary endothelial cells from WT and Bmpr2+/R899X mice to assess the 
capacity of BMP9 to enhance monolayer integrity in vitro. As with BMPR2 mutation-
bearing BOECs, endothelial monolayers from Bmpr2+/R899X mice displayed increased 
permeability both at baseline and following LPS stimulation. BMP9 prevented LPS-induced 
permeability in endothelial monolayers from both WT and Bmpr2+/R899X mice (Fig. 4g; 
Supplementary Fig. 10c, d). In vivo, Bmpr2+/R899X and WT mice injected with LPS 
developed pulmonary vascular leak, quantified by extravasation of Evans blue dye into lung 
tissue (Fig. 4h). Bmpr2+/R899X mice demonstrated increased dye extravasation compared to 
WT littermates, which was blocked with BMP9 to a similar degree in both groups (Fig. 4i).
To further exclude the possibility that BMP9 was acting through a direct effect on smooth 
muscle, we isolated PASMCs from WT and Bmpr2+/R899X mice. While BMP4 reduced 
PASMC proliferation, BMP9 had no effect (Supplementary Fig. 10e, f).
BMP9 reverses monocrotaline-induced pulmonary hypertension
We assessed the efficacy of BMP9 treatment in the monocrotaline rat model of PAH, a non-
genetic model of disease in which reduction of BMPR-II expression is a central feature7,34. 
BMP9 treatment for 21 days (600 ng/day, i.p.) immediately following exposure to 
monocrotaline prevented elevation of RVSP, right ventricular hypertrophy and pulmonary 
arterial muscularization (Fig. 5a–d). In a protocol where BMP9 dosing was commenced 3 
weeks after monocrotaline, in the presence of the established PAH, two weeks of daily 
BMP9 treatment inhibited the progression of PAH (Fig. 5c–f). In agreement with our 
previous reports, rats treated with monocrotaline displayed reduced lung BMPR-II protein 
levels and impaired canonical BMP signaling (Supplementary Fig. 11a–d). Treatment with 
BMP9 from days 0 to 21 restored BMPR-II levels and downstream signaling to near normal 
levels.
Endothelial apoptosis is believed to be a primary factor in the initiation of PAH models16,17 
and human disease15. Staining of lung tissue for cleaved caspase-3 not only revealed 
enhanced pulmonary endothelial cell apoptosis at five days post-monocrotaline, but also in 
established disease at three weeks post-monocrotaline (Fig. 5g, h). Daily administration of 
BMP9 prevented enhanced apoptosis at both time points. Immunoblotting of whole lung 
lysates confirmed a reduction in total cleaved caspase-3 in response to BMP9 at both three 
and five weeks post-monocrotaline (Supplementary Fig. 11e).
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BMP9 reverses Sugen-hypoxia induced pulmonary hypertension
We also examined the efficacy of BMP9 in the more severe PAH model of rats exposed to 
chronic hypoxia in combination with the VEGF receptor blocker SU-541617 (Fig. 6a). Rats 
given SU-5416 and exposed to three weeks of hypoxia (10% O2) and an additional 5 weeks 
of normoxia developed severe pulmonary hypertension and right ventricular hypertrophy 
(Fig. 6b–c) as well as extensive pulmonary arterial muscularization (Fig. 6d–e). Daily BMP9 
(600 ng/day, i.p.) from weeks 8 to 11 resulted in a reversal of established disease, including 
a reduction in RVSP, RV hypertrophy and vascular remodeling when compared to saline-
treated controls (Fig. 6b–e).
Established disease was also accompanied by the concurrent formation of both angio-
obliterative lesions (Fig. 6f, h) and heightened endothelial cell apoptosis (Fig. 6g), as well as 
reduced Smad1/5 phosphorylation (Supplementary Fig. 12a–b), all of which were reversed 
by BMP9. Immunoblotting of whole lung lysates for cleaved caspase-3 and PCNA further 
supported the capacity of BMP9 to simultaneously prevent excessive endothelial cell 
apoptosis and pathological angiogenesis in this model (Supplementary Fig. 12a). While 
BMP9 did not reverse elevated VEGFA gene expression in the lungs of rats treated with 
SU-5416 and hypoxia, it did block VEGF-induced endothelial cell proliferation and tube 
formation in vitro (Supplementary Fig. 12c–i). Assessment of LV function revealed no 
significant changes in cardiac output in diseased animals given BMP9 or saline when 
compared to healthy controls (Supplementary Table 1).
Similarly, mice given SU-5416 and exposed to three weeks of hypoxia (10% O2) developed 
moderate-to-severe pulmonary hypertension and right ventricular hypertrophy, accompanied 
by increased pulmonary arteriolar muscularization (Supplementary Fig. 13a–c). 
Administration of BMP9 (75 ng/day, i.p.) throughout the period of treatment with SU-5416 
and hypoxia resulted in normalization of right ventricular systolic pressure and right 
ventricular mass, and abrogated the muscularization of small arterioles. Treatment of mice 
with BMP9 did not result in heterotopic ossification at the sites of i.p. injection, based on x-
ray and micro-CT analysis (Supplementary Fig. 13d). Moreover, daily intramuscular 
injection of mice with BMP9 (75 ng/day) for 3 weeks failed to elicit intramuscular 
heterotopic ossification (Supplementary Fig. 13e).
Discussion
We report the first use of a BMP ligand to target and enhance endothelial BMPR-II 
signaling and reverse established PAH in animal models of disease. This work is also the 
first to show that mice heterozygous for a human disease causing mutation are susceptible to 
PAH, providing a new genetic model for this disease that, unlike previous models, closely 
mimics the human genetics of PAH.
One challenge associated with therapeutic application of BMPs for the treatment of PAH is 
the identification of a ligand that preferentially targets the pulmonary endothelium. Our 
array screen of PAECs treated with different BMP ligands demonstrated the superiority of 
BMP9 for stimulating the pulmonary endothelium. Of note is our observation that BMP2, 4 
and 6 possess minimal ability to stimulate PAECs, which at first sight contrasts with other 
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previously published findings. This discrepancy can be largely accounted for by differences 
in the concentrations of BMPs used. The majority of papers describing a response of 
endothelial cells to BMP2, 4 or 6 used concentrations in excess of 10ng/ml and often use a 
range of 50–200 ng/ml15,35. Here we show the response of PAECs to BMP9 is already 
maximal at 1 ng/ml. These findings demonstrate that other BMPs may be used to stimulate 
the endothelium, but only at high doses that will have no selectivity for the endothelium and 
likely promote heterotopic ossification. In contrast, BMP9 allows for selective stimulation of 
canonical BMP signalling in pulmonary endothelial cells at concentrations that do not 
induce signaling in PASMCs and do not promote ossification. As ALK1 is also expressed in 
hepatocytes, mesenchymal cells, chondrocytes and cardiomyocytes, we cannot categorically 
exclude non-endothelial mechanisms of BMP9 treatment.
In vitro and in vivo studies confirmed the capacity of BMP9 to block apoptosis and enhance 
vascular stability, two pathways critically dysregulated in the pathogenesis of PAH15–20. 
The ability of BMP9 to prevent endothelial apoptosis in vitro is in agreement with previous 
studies that reported the anti-apoptotic effect of various BMP ligands15,36. Despite the fact 
that this action of BMP9 is dependent on BMPR-II, we were able to show that BMP9 
provides protection in BMPR2 mutation-bearing BOECs, presumably due to increased 
ligand interaction and signaling via the wild type receptor. We demonstrate that BMP9 
inhibited endothelial permeability induced by a variety of agents relevant to PAH. 
Endothelial permeability is increasingly implicated in PAH pathobiology and a recent study 
identified that loss of BMPR-II promotes SRC-dependent caveolar trafficking defects in 
heritable PAH as a potential mechanism37.
Beyond the direct effects of BMP9 on endothelial cell function, we demonstrate the capacity 
of BMP9 to increase BMPR-II levels via a Smad-binding region on the BMPR2 promoter. In 
canonical BMP signaling, interactions of ligands with heterodimers of type I and type II 
receptors leads to phosphorylation of a restricted set of receptor activated Smad proteins 
(Smads 1,5 and 8). However, non-Smad mediated BMP signaling is involved in certain 
cellular responses. Despite the recent identification of rare mutations in Smad1 and Smad8 
in individuals with PAH38,39, the relative contribution of Smad and non-Smad mediated 
signaling to the pathobiology of PAH remains uncertain. Our observation that compound 
heterozygous mice, bearing loss-of-function mutations in both Bmpr2 and Smad1, develop 
more severe spontaneous PAH than that observed in mice heterozygous for Bmpr2 alone 
supports a central role for the canonical BMPR-II/Smad signaling pathway in PAH. This is 
supported by a previous study showing that conditional deletion of Smad1 in endothelial 
cells in mice promotes the development of PAH40.
Our report of the spontaneous development of PAH in the Bmpr2+/R899X knock-in mouse is 
a major development, which for the first time provides an experimental model of disease 
that closely mimics the human genetics of PAH, leading to NMD of the mutant transcript. 
Although Bmpr2+/R899X mice spontaneously develop elevated right ventricular systolic 
pressures and enhanced pulmonary arteriolar muscularization at 6 months of age, these 
changes were not accompanied by right ventricular hypertrophy. One possibility is that the 
modest increase in RVSP in these mice (~35mmHg) was not sufficient to induce measurable 
RV hypertrophy. This possibility is supported by the fact that compound Bmpr2+/R899X/
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Smad1+/− heterozygotes did develop RV hypertrophy in response to a more severe elevation 
of RVSP. Alternatively, a recent reports in a pulmonary arterial banding model of RV 
hypertrophy showed that the transgenic expression of a stabilized form of mutant Bmpr2-
R899X in the heart results in reduced RV remodeling associated with intra-cardiomyocyte 
lipid deposition41. It is noteworthy that aged Bmpr2+/R899X mice are susceptible to PAH, 
whereas Bmpr2 heterozygous null mice are not. There is no clear explanation for this 
observation, since both would be expected to result in haploinsufficiency. It remains 
possible that incomplete NMD of the mutant transcript in Bmpr2+/R899X mice plays a role, 
although we found no evidence for this.
The finding that BMP9 treatment reverses established disease in three animal models of 
PAH is critical, as any viable treatment will need to be effective in a patient population that 
typically presents with advanced disease. The capacity of BMP9 to reverse disease in the 
Sugen-hypoxia model is a particularly important indicator of the clinical suitability of this 
treatment strategy, as it is the only model to recapitulate the intimal lesions and advanced 
vascular remodeling observed in individuals with PAH. In these models, we have shown 
that, as in our cultured endothelial cells, BMP9 promotes vascular stability by 
simultaneously preventing apoptosis and blocking pathological angioproliferation. Our 
observation of increased endothelial apoptosis at later time points in both the monocrotaline 
and Sugen-hypoxia rat models support the suggestion that endothelial apoptosis is not only a 
driving factor in disease onset, but an ongoing phenomenon in established disease, occuring 
concurrently with pathological angioproliferation. This finding is supported by our 
observation that BMPR2 mutation-bearing BOECs are more susceptible to apoptotic stimuli 
even when isolated from individuals with established PAH.
In conclusion, our work provides proof-of-concept for the treatment of PAH through the 
direct enhancement of endothelial BMPR-II signaling with BMP9. BMP9 not only protects 
pulmonary arterial endothelial cells from apoptosis and promotes vascular stability, but also 
increases BMPR2 gene expression, allowing for further enhancement of BMPR-II signaling. 
These effects were still observed in cells derived from individuals bearing mutations in 
BMPR2, suggesting that this treatment might be efficacious in PAH patients with or without 
a mutation. Taken together, our findings suggest that approaches based on targeting the 
canonical endothelial BMPR-II/ALK1 complex using recombinant ligands or small 
molecule receptor agonists may provide a promising new approach for the treatment of 
PAH.
Online Methods
Cell Culture
Human ECs were purchased from Lonza (Basel, Switzerland). PAECs, HUVECs, HAECs 
and HMEC-1 cells were cultured in EGM-2 with 2% FBS (Lonza), as per supplier’s 
instructions. Human BOECs were generated from 40–80 mL peripheral blood, as described 
previously42. BOECs were cultured in EGM-2MV with 10% standard grade FBS (Life 
Technologies, Carlsbad, CA) and were used for experiments between passages 4 and 8. 
Unless specified otherwise, treatment of human endothelial cells with BMPs was performed 
in EBM-2 (Lonza) with 0.1% FBS.
Long et al. Page 9
Nat Med. Author manuscript; available in PMC 2016 January 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
The endothelial nature of BOECs was assessed by flow cytometery for endothelial surface 
marker expression as described previously42. All cell lines were routinely tested for 
mycoplasma contamination. For BOEC generation, all blood donors provided informed 
consent in accordance with human study 07/H0306/134 (Cambridgeshire 3 Research Ethics 
Committee). Information on the specific BMPR2 mutations present in BOECs is specified in 
Supplementary Table 2.
Mouse lung microvascular endothelial cells were isolated as described previously43 with 
minor modifications. Briefly, minced lung tissue was digested for 30 minutes at 37°C in 
2mg/mL Collagenase I (Sigma Aldrich, St. Louis, MO), dissolved in DPBS with calcium 
and magnesium and filtered through a 70μm cell strainer. The resultant cell suspension was 
incubated for 10 minutes at room temperature with sheep anti-rat IgG Dynabeads (Life 
Technologies), pre-conjugated with rat anti-mouse PECAM-1 (BD-Pharmingen, Franklin 
Lakes, NJ). Magnetically isolated cells were washed multiple times DMEM and plated on 
tissue culture plates pre-coated with 0.1% gelatin (Sigma) for 24 hours in Endothelial 
Growth Medium, consisting of DMEM with 20% FBS, 1x Penicillin-Streptomycin-
Glutamine (Life Technologies), 0.1mg/mL heparin (Sigma) and 0.1mg/mL Endothelial Cell 
Growth Factor (Biomed Tech Inc, Ward Hill, MA). After 24 hours, cultures were washed to 
remove non-adherent cells and allowed to grow for 5–9 days until near confluent. Cells were 
then trypsinized and endothelial cells were purified by a second round of positive magnetic 
selection with Dynabeads. Resultant endothelial cells, which grow with a typical 
cobblestone morphology, were then re-plated on gelatin coated plates in Endothelial Growth 
Medium.
Human and mouse PASMCs were isolated and cultured as described previously.44 Unless 
specified otherwise, tretament of PASMCs with BMPs was performed in DMEM with 0.1% 
FBS.
Microarray
PAECs (n=4) or BOECs (n=3) from healthy subjects were quiesced in M199 media with 
0.1% FBS for 12 hours prior to a 4 hour stimulation in new media with vehicle, 1 ng/mL 
BMP9, 10 ng/mL BMP2 or 10 ng/mL BMP6 (all from R&D Systems, Minneapolis, MN). 
Cell monolayers were lysed in Trizol and purified mRNA was hybridized to Human 
Genome U133 Plus 2.0 GeneChips (Affymetrix, Santa Clara, CA). Quality control, 
background correction and normalization were performed using R/Bioconductor (http://
bioconductor.org). Differential gene expression was assessed by fitting linear models and 
resulting p-values were adjusted for multiple testing45. Enrichment of gene-sets was 
determined using Generally Applicable Gene-set Enrichment (GAGE)46 and Signaling 
Pathway Impact Analysis (SPIA)47. Pathway diagrams were generated with the pathviews 
package48. The pathway maps of interest, i.e. “Environmental Information Processing” and 
“Cellular Processes” were retrieved from the Kyoto Encyclopedia of Genes and Genomes 
(KEGG) database. Microarray data are available in the ArrayExpress database 
(www.ebi.ac.uk/arrayexpress) under accession number E-MTAB-2495.
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siRNA knockdown and qPCR
Cells were maintained in Optimem serum free medium (Life Technologies) for 3 hours prior 
to the addition of Dharmafect 1 transfection reagent with or without siRNAs for Smad1, 
Smad5 or BMPR2 or a control pool of oligonucleotides (all Thermo Fisher, Waltham, MA) 
for 4 hours. After siRNA treatment, cells were returned to culture media for 24 hours prior 
to use. qPCR for Smad1, Smad5, BMPR2 or VEGFA mRNA was performed as described 
previously30 and presented relative to GAPDH, β-2 microglobulin, HPRT, β-actin, or a 
combination of these housekeeping genes.
Western Blotting
After the indicated duration of treatment, cells were lysed in phosphate buffered saline 
(PBS) containing 50mM Tris pH 8.0, 1% igepal, 0.1% SDS, 0.5% sodium deoxycholate and 
Roche complete protease inhibitor cocktail (Roche, Basel, Switzerland). Lysates were 
sonicated and frozen at −80°C until used. Cell lysates (20–40μg total protein) were separated 
on reducing SDS-PAGE gels and proteins were transferred to polyvinylidene fluoride 
membranes by semi-dry blotting. Membranes were then blocked and probed with rabbit 
polyclonal antibodies towards JNK (catalogue # 9252), phospho-JNK (catalogue # 9251), 
Smad1 (catalogue # 9743), phospho-Smad1/5/8 (catalogue # 9511, all Cell Signaling 
Technology, Danvers, MA) or PCNA (catalogue # ab18197, Abcam, Cambridge, UK), 
rabbit monoclonal antibodies towards Caspase-3 (clone 8G10), cleaved Caspase-3 (clone 
5A1E), phosphorylated Smad1/5 (clone 41D10, all Cell Signaling Technology, Danvers, 
MA), Smad5 (clone EP619Y, Epitomics, Burlingame, CA), Id1 (clone 195-14) or Id3 (clone 
17-3, both CalBioreagents, San Mateo, CA) or a mouse monoclonal antibody towards 
BMPR-II (clone 18/BMPR-II, BD Transduction Laboratories, Franklin Lakes, NJ). As a 
loading control, all blots were re-probed with a monoclonal antibody towards either α-
tubulin (clone DM1A) or β-actin (clone AC-15, Sigma). Densitometry was performed using 
ImageJ software.
Chromatin Immunoprecipitation (ChIP) Assay
ChIP assays were performed using a chromatin immunoprecipitation assay kit (Millipore, 
Billerica, MA) in accordance with the manufacturer’s instructions. HMEC-1 cells at 80–
90% confluency were assayed either at baseline, 72 hours after siRNA knockdown of 
Smad1 or following a 24 hour stimulation with 1 ng/mL BMP9. Cells were cross-linked 
with 1% formaldehyde for 10 minutes at 37°C. 125mM glycine was added to block cross-
linking. Cells were then rinsed with PBS and lysed in 200μl buffer containing 1ug/ml 
aprotinin, pepstatin, and 1mM phenylmethylsulfonul fluoride. Chromatin samples were 
sonicated with 4 sets of 10-second pulses on wet ice using a Cole Parmer, High Intensity 
Ultrasonic Processor/Sonicater, 50-watt model equipped with a 2mm tip and set to 30% 
maximum power to reduce the DNA length to 200–1000bp. The sonicated lysate was then 
diluted to 2ml with dilution buffer containing a protease inhibitor cocktail. After preclearing 
with salmon sperm DNA/Protein A-agarose for 1h at 4°C, 20μl (1%) of this solution was 
removed for later PCR analysis (input). 2μg of the immunoprecipitating antibodies towards 
C-terminal phospho-Smad1/5 or Smad4 (catalogue # 9515, Cell Signaling Technology) were 
added to the remaining sample (for the negative control, rabbit polyclonal IgG was added), 
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and the sonicated lysates were incubated overnight at 4°C. Immune complexes were 
collected with 60μl of salmon sperm DNA/Protein A-agarose (1h at 4°C), and agarose beads 
were washed with solutions of increasing ionic strength. After a final wash, bound immune 
complexes were eluted in a freshly prepared solution of 1% SDS, 0.1M NaHCO3, and cross-
links were reversed in the samples (and the input from the sonicated lysates) by heating at 
65°C overnight. Samples were then treated with Proteinase K, and DNA was phenol/
chloroform-extracted and precipitated. DNA was resuspended in 20μl H2O, and 1μl was 
used for detection of the BMPR2 promoter by PCR using the oligonucleotides 5′-
GAACACATCAAAGGGGTGGT-3′ and 5′-GTGGCCTTTCTCCTTCACAC-3′, which 
together amplify 350bp spanning from −1797 to −1448 of the promoter region. DNA from 
the input was resuspended in 20μl, and 1μl was used for PCR.
BMPR2 Promoter Constructs
A 5kb fragment of the human BMPR2 promoter was generated by polymerase chain reaction 
(PCR) from BAC clone RP11-68606. A 5′ primer (5′-GCG CGA GCT CTA GTC CTC CCT 
GCC CCT TAT-3′), including a Sac I site for subcloning, and a 3′ primer (5′-GCG CAA 
GCT TAG CAG GAT GGT CCA TGG TAG-3′) initiating 59bp upstream of the 
transcription start site and containing a Hind III site, were used. The amplified product was 
purified and cloned into the Sac I/Hind III-digested promoter-deficient reporter vector 
pGL3-basic (Promega, Madison, WI) to give the BMPR2-luc construct. The putative Smad 
binding site on the BMPR2 promoter was mutated using the PCR-based QuickChange Site-
Directed Mutagenesis kit (Stratagene, La Jolla, CA) and the following primers Fwd: 5′-
GCTCTGCACCACAGGCTAGAGtgAtcCAGGGCCGGGAAGAG-3′; Rev: 5′-
CTCTTCCCGGCCCTGgaTcaCTCTAGCCTGTGGTGCAGAGC-3′, with the binding site 
indicated in bold and the desired point mutations indicated in lowercase. PCR products were 
digested with Dpn I to elimate parental DNA. Recombinant DNA was verified by 
sequencing.
Transfection of HMEC-1 cells
HMEC-1 cells were seeded onto 24-well plates at a density of 8×104 cells per well 24 hours 
before transfection. The transfection was performed with LipofectAMINE2000 reagent 
(Invitrogen, UK). Typically 1μg of plasmid DNA was mixed with 2μl of 
LipofectAMINE2000. Fresh culture medium was changed 24h after transfection. 48 hours 
post-transfection, cells were washed with PBS and lysed. Nuclear-free supernatants were 
analysed for luciferase reporter gene activity (Roche Molecular Biochemicals, Germany) 
and corrected for protein content.
Induction of and assessment of apoptosis by Annexin-V and Propidium Iodide staining
Sixteen hours prior to the addition of an apoptotic stimulus, PAECs or BOECs were 
transferred into EBM-2 basal media (Lonza) with 2% FBS, 100 U/mL penicillin, 100 
mg/mL streptomycin and 0.25 mg/mL amphotericin B, but without any growth factor 
supplements. During this incubation, cells were maintained with or without 5 ng/mL BMP9 
for indicated period. Following the 16-hour incubation, cells were either left unstimulated or 
treated for 3 or 6 hours with 10 ng/ml TNFα and 20 μg/mL cyclohexamide to induce 
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apoptosis. For measurement of total and phospho-JNK, cells were lysed after 3 hours and 
lysates were assessed by immunoblotting. For assessment of apoptosis, cells were incubated 
for 6 hours after the apoptotic stimulus and either lysed for the assessment of cleaved 
caspase-3 by immunoblotting or trypsinized, stained with FITC-conjugated annexin-V and 
propidium iodide (PI, BD Biosciences) as per manufacturer’s instructions and assessed by 
flow cytometry. Apoptotic cells were considered to be positive for annexin-V and negative 
for PI.
Assessment of endothelial monolayer permeability
Monolayer permeability was assessed as described previously49. Briefly, transwell inserts 
(Corning, Corning, NY) were coated for 1 hour at 37°C with 0.1 mg/mL bovine skin 
collagen (Sigma), washed with water 2 times and rinsed with medium prior to plating cells. 
Cells (4×105 in 100 μl complete EGM-2 medium) were plated in the top chamber and 700 μl 
of medium was added to the bottom chamber 24 hours prior to the addition of fresh medium 
to both chambers, with or without 10 or 20 ng/mL BMP9 in the upper chamber (as 
indicated). After 30 minutes, 25 nM horseradish peroxidase was added to the top chamber, 
with or without 0.4ug/ml LPS (Sigma), 1U/mL thrombin (Sigma) or 50 ng/mL TNFα (R&D 
Systems). Medium (20μl) was collected from the lower chamber every 30 minutes for 2 
hours. HRP content of the media samples was determined by measuring absorbance after the 
addition of 150μl of o-Phenylenediamine dihydrochloride buffer to each well of a 96-well 
plate.
For VE-cadherin assays, PAECs were cultured in EBM-2 media (Lonza) with 2% FBS for 
24 hours with or without LPS, thrombin, TNFα and/or 10 ng/mL BMP9. Cells were then 
stained with FITC-conjugated rabbit polyclonal anti-VE-cadherin (cat #: LS-C40121, 1:100, 
Lifespan Biosciences, Seattle, WA).
Cell Proliferation assays
For assessment of PAEC proliferation, cells were seeded at 30000 cells/well in 24-well 
plates and left to adhere overnight. Cells were the washed with EBM2 containing 0.1% FBS 
and then serum-restricted in EBM-2 containing 0.1% FBS. Cells were then treated with 
BMP9 (5ng/ml), VEGF165 (30ng/ml, both R&D Systems) or both ligands combined in 
EBM2 containing 2% FBS and treatments were replenished after 48 hours. After 72 hours of 
ligand exposure, cells were trypsinised and counted using trypan blue exclusion to assess 
cell viability.
Proliferation of mouse PASMCs was determined as described previously44, in the presence 
of 1 ng/mL BMP9 or 10 ng/mL BMP4.
Endothelial tube formation assays
PAECs were cultured in a collagen and fibronectin gel matrix as previously described50. 
Briefly, cells were combined with the gel at a final concentration of 1×106. The suspension 
was then pipetted into an angiogenesis μ-slide (Ibidi, Germany) in a volume of 10 μl/well. 
After 10 minutes at 37°C to allow polymerization, the gel was overlaid with 40μl of media 
(EBM-2, Lonza and 2% FBS), with or without 5 ng/ml BMP9 or 30 ng/mL VEGF165 (both 
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R&D Systems) individually or combined. The 3-D cultures were left at 37°C for 24 hours 
and tube formation confirmed by brightfield microscopy. Images were collected and 
parameters measured and quantified using Image J software. In order to gain confocal 
images, gels were first fixed in 4% PFA, washed in PBS and incubated with Rhodamine 
labelled ULEX Europaeus Agglutinin1 (Vector Laboratories, Burlingame, CA) overnight at 
4°C. After 3× 10 minute PBS washes, nuclear staining was carried out using 10μl of 
VectorSHIELD mounting media with DAPI (Vector Laboratories) for 30 minutes. A final 
x3 wash in PBS was completed.
Rodent models of PAH
For all animal work, group sizes were determined using estimates of variance and minimum 
detectable differences between groups that were based on our past experience with rodent 
models of PAH. Animals were randomized using an assigned animal identification number, 
allowing investigators performing all cardiopulmonary phenotyping procedures and 
histological analyses to be blinded to animal genotype and treatment group. All animal work 
was carried out in accordance with the UK Animals (Scientific Procedures) Act 1986 and 
approved under Home Office Project Licence 80/2460.
Mice
All mice used in this work possessed a C57Bl/6 background. Smad1+/− mice were obtained 
as a generous gift from the late Dr Anita Roberts33. For Bmpr2+/R899X mice, both male and 
female mice were studied. For Smad1+/− mice and Smad1+/−/Bmpr2+/R899X compound 
heterozygotes, as well as littermate controls, only male mice were examined.
Creation of Bmpr2+/R899X mice
A gene targeting vector was created containing a 4.69kb 5′ homology arm and a 1.84kb 3′ 
homology arm, separated by a loxP flanked neomycin expression cassette (Supplementary 
Fig. 8). The 5′ homology arm, consisting of 4.69kb of intron 11, exon 12 and 30 bp of intron 
12, was cloned into the pNTFLOX (kind gift of Dr. Jim Hughes) vector between the XhoI 
and NotI restriction sites using the following primers Fwd: 5′-GATC CTCGAG 
GTAAGGTCCT GAGGGGTTTG-3′; Rev: 5′-
GATCGCGGCCGCCAAAGGGTACTGCATAACCCCT-3′. The 1.84kb 3′ homology arm, 
consisting of intron 12 and exon 13, was cloned into PacI and KpnI sites using the following 
primers: Fwd: 5′-GATCTTAATTAAGGACAGTTAA ATAAAATAGA-3; Rev: 5′-
GATCGGTACCTCACAGACAATTCATTCCTA-3′. The R899X substitution mutation was 
introduced into exon 12, 200bp upstream of the 3′ end of the 5′ homology arm using the 
Stratagene Quickchange site-directed mutagenesis kit and the following primers: Fwd: 5′-
CCATTAGAAGGTGGCTGAACAAATTCCAAT-3′; Rev: 5′-
ATTGGAATTTGTTCAGCCACCTTCTAATGG-3′ following manufacturer’s instructions. 
For homologous recombination, the 5′ homology arm was truncated to 1.72 kb and the 
resulting targeting vector was transfected into 129S3 mouse embryonic stem (ES) cells by 
electroporation. Neomycin resistant ES cell colonies were screened by polymerase chain 
reaction for homologous recombination. Correct targeting was confirmed by Southern blot 
using a neomycin-specific probe that allowed for the exclusion of random integration events 
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of the targeting vector. Selected targeted ES cells were injected into C57Bl/6 blastocysts and 
chimeric mice were bred with C57Bl/6 females, resulting in heterozygous R899X offspring 
that were back-crossed to C57Bl/6 for >5 generations.
Cardiopulmonary phenotyping, tissue collection and BMP9 treatment in mice
Three or six month-old mice were mice were anaesthetized with xylazine (4.6 mg/kg) and 
ketamine (7 mg/kg) and right and left ventricular pressures and volumes were recorded 
using a Millar PVR-1045 catheter (Millar Instruments, Houston, TX). Mice were then 
sacrificed and the hearts and lungs were harvested. Right ventricular hypertrophy was 
determined as a ratio of right ventricular to left ventricular and septal weight (RV/LV+S). 
The right lung was snap frozen in liquid nitrogen. The left lung was inflated with a 1:1 
mixture of saline and OCT (Sakura, Zoeterwoude, Netherlands) and fixed with 4% 
paraformaldehyde in PBS prior to dehydration and paraffin embedding. A separate group of 
six month-old Bmpr2+/R899X mice and WT littermate controls were given daily i.p. 
injections of recombinant human BMP9 (75 ng/mouse/day, gift from Pfizer) for 28 days 
prior to evaluation of cardiopulmonary haemodynamics.
Monocrotaline rat model
Male Sprague Dawley rats (~200 to 250 grams, Charles River, Margate, UK) were 
randomized into three groups. Control rats were given intraperitoneal injections of sterile 
water as a vehicle control. Rats on the prevention protocol were given 60 mg/kg of MCT 
(Sigma, St. Louis, MO) by i.p. injection and treated with daily i.p. injections of recombinant 
human BMP9 (600 ng/day) or vehicle control from day 0 until sacrifice on days 2, 5 or 21. 
Rats on the reversal protocol were given 40 mg/kg of MCT, allowed to develop PAH from 
days 0 to 21, and treated with BMP9 (600 ng/day) or vehicle control from day 21 to sacrifice 
on day 35. At the time of sacrifice, animals were anaesthetized with xylazine (4.6 mg/kg) 
and ketamine (7 mg/kg) and right and left ventricular function were assessed using a Millar 
SPR-869 pressure-volume catheter. Tissue harvesting was carried out as described above for 
mice.
SU-5416-chronic hypoxia rat model
Male Sprague Dawley rats (~150 to 200 grams, Charles River) were given a single 
intraperitoneal injection of SU-5416 (20 mg/kg, Tocris, Bristol, UK) in vehicle (0.5% 
carboxyl methylcellulose sodium, 0.4% polysorbate 80, 0.9% Benzyl alcohol, all Sigma), 
placed immediately into a 10% O2 chamber and maintained in hypoxia for 3 weeks, 
followed by 5 weeks in a normoxic environment to develop pulmonary hypertension. At the 
8-week time point, rats were randomized into 3 groups. One group was assessed for 
cardiopulmonary function and sacrificed as described for the monocrotaline model above, 
while the other two groups received 3 weeks of daily i.p. injections with 600 ng/day BMP9 
or saline vehicle as a control prior to cardiopulmonary phenotyping and sacrifice as 
described above.
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SU-5416-chronic hypoxia mouse model
Six month-old male C57/BL6 mice (~30–35 g, Charles River) were given weekly 
subcutaneous (infrascapular) injections of SU-5416 (20 mg/kg) in vehicle (0.5% carboxyl 
methylcellulose sodium, 0.4% polysorbate 80, 0.9% Benzyl alcohol, all Sigma), placed 
immediately into a 10% O2 chamber and maintained in hypoxia for 3 weeks. During this 
treatment period, mice were randomized into 4 groups. One group received vehicle alone 
without hypoxia or SU-5416, while another group received BMP9 (75 ng/day in saline i.p.) 
daily injections without hypoxia or SU-5416. Among mice receiving hypoxia and SU-5416, 
one group received vehicle while the remainder received BMP9 daily injections. In addition, 
a cohort of mice maintained in normoxia received daily intramuscular injections of BMP9 
(75 ng/day) into the right hamstring muscle. Mice were assessed for cardiopulmonary 
function and sacrificed as described for the genetic mouse model above, and then subjected 
to conventional x-ray (Carestream in vivo imager) and micro-CT analysis (ScanCo μCT40).
Assessment of Nonsense Mediated Decay
PASMCs were seeded in 6cm plates and grown to approximately 1 × 103 cells/plate. 
Puromycin (Sigma) was added to 100 μg/ml for 20 h prior to harvesting. Parallel plates with 
and without puromycin were harvested for RNA analysis and a third plate for DNA. DNA 
was extracted using the QIAamp DNA Mini Kit (Qiagen, Valencia, CA) and RNA using the 
miRNeasy Mini Kit with on-column DNase treatment. First-strand cDNA synthesis was 
performed using Superscript III (Life Technologies, Carlsbad, CA) with random hexamer 
priming. The region of BMPR2 exon 12 containing the R899X mutation was analyzed by 
dideoxy sequencing of PCR products (conditions and primers available on request). To 
ensure specificity for the target nucleic acid, DNA was amplified using an intronic reverse 
primer and RNA was amplified with primers spanning intron 12.
Immunohistochemistry
For assessment of pulmonary arteriolar muscularization, sections of fixed rat lung tissue 
(5μm) were labeled with monoclonal mouse-anti-mouse/rat/human smooth muscle α-actin 
(clone 1A4, Dako, Glostrup, Denmark), followed by polyclonal goat anti-mouse HRP. For 
mouse lung tissue, Dako ARK™ was used in accordance with the manufacturer’s 
instructions. Briefly, the primary antibody was labeled by a modified biotinylated anti-
mouse immunoblobulin prior to application to the specimen. The primary antibody and 
Biotinylation Reagent were mixed in solution, resulting in binding of biotinylated secondary 
antibody to the primary antibody. The Blocking Reagent, containing normal mouse serum, 
was then added to the mixture to bind residual Biotinylation Reagent not bound to the 
primary antibody, minimizing potential interaction with immunoglobulin endogenous in the 
specimen. The biotin-labeled primary antibody was then applied to the specimen followed 
by incubation with streptavidin-peoxidase and reaction with diaminobenzidine (DAB)/
hydrogen peroxide as substrate-chromogen.
Assessment of pulmonary arteriolar muscularization involved the identification of alveolar 
ducts and the subsequent categorization of the accompanying intra-acinar artery as non, 
partially or fully muscularized. A minimum of 20 vessels with diameters ranging from 25 to 
75 μm were counted from non-serial lung sections and categorized as either fully, partially 
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or non-muscularized. Statistical significance was assessed by comparing the percentage of 
fully muscularized vessels between groups. Assesment of muscularization was performed 
blinded.
Alternatively, immunofluorescent assessment of mouse lung sections was performed using 
rabbit anti-vWF (Dako A0082) at 1:200 in 5% goat serum, followed by Alexa-488 
conjugated anti-rabbit secondary antibody (Molecular Probes), as well as monoclonal anti-
SM alpha actin (Sigma) at 1:100 in 5% goat serum followed by Alexa-555 conjugated anti-
mouse secondary antibody (Molecular Probes).
For assessment of neointima formation, rat lung sections were also stained with Elastic Van 
Gieson (EVG) stain and examined by light microscopy. Quantification of endothelial cell 
apoptosis in rat lungs was performed by staining fixed rat lung sections with a rabbit 
monoclonal antibody towards cleaved caspase-3 (clone 5A1E, Cell Signaling Technology) 
or a rabbit polyclonal antibody towards vonWillebrand factor (catalogue # ab9378, Abcam, 
Cambridge, UK) and labeled using immunoperoxidase (Vectastain Elite, Vector 
Laboratories) and 3,3′-DAB to create a brown coloured reaction product. Cleaved caspase-3 
positive cells on the luminal surface of 25 to 75 μm pulmonary vessels were vascular were 
quantified and normalized to total tissue area using Image J.
Ex-vivo stimulation of rat pulmonary artery and subsequent staining for phosphorylated 
Smad1/5 was performed as described previously for rat aortas51. Isolated pulmonary arteries 
were stimulated ex vivo for 1 hour with 5 ng/mL BMP9 prior to fixation and paraffin 
embedding.
Evans Blue Dye Permeability Assay
Permeability of Evans blue dye in response to LPS challenge was determined as described 
previously52. Briefly, animals were injected i.p. with 2mg/kg LPS (Sigma Aldrich) or 
vehicle and either 36.79 ng/25g recombinant human BMP9 or vehicle 22 hours prior to the 
i.p. injection of 6 mL/kg of 1% Evans blue dye in PBS with 4% bovine serum albumin 
(equivalent to 20 mg/kg Evans blue). Two hours after the injection of Evans blue, animals 
were sacrificed, the left atrium was clipped and the lung vasculature was flushed with 10mL 
of PBS per mouse via the right ventricle to remove intravascular EB. Flushed lungs were 
photographed and right and left lungs were separately weighted and snap frozen in liquid 
nitrogen. Right lungs were homogenized in formamide (1ml/100mg lung), and incubated for 
24 hr at 37°C. Homogenates were clarified by centrifugation at 12,000 g for 20 min and the 
absorbance of 200μl of clarified supernatant was measured at 620nm in a 96-well plate.
Statistical Methods
Student’s t-tests were used for comparisons between two groups. Multiple comparisons were 
assessed by one-way ANOVA, followed by the appropriate post-hoc test for significance, as 
specified in the figure legends. Equivalence of variance between experimental groups was 
confirmed using an F-test for comparisons between two groups and a Brown-Forsythe test in 
conjunction with ANOVA, when applicable. Normal distribution was assumed for all 
statistical analyses and confirmed when group sizes allowed for testing of normality. All 
statistical tests used two-sided tests of significance. All data are reported as mean +/− SEM.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. BMP9 preferentially stimulates hPAECs
Volcano plots of differentially expressed genes in PAECs treated with (a) 1 ng/mL BMP9, 
(b) 10 ng/mL BMP6 or (c) 10 ng/mL BMP2 versus control after fitting linear models and 
adjusting P values for multiple testing (FDR). Differentially expressed genes of the TGF-β 
pathway are highlighted in grey. Dashed lines represent an adjusted P value of 0.05 and a 
fold change of +/− 1x. (d) Heat map showing whole gene-set perturbation (test statistics) of 
regulated pathways in PAECs following BMP9 treatment. (e) Signaling pathway impact 
analysis (SPIA) to detect alterations in common signaling pathways in PAECs in response to 
BMP9 treatment. Corrected for false discovery rate. (f) Immunoblotting for phosphorylated 
Smad1/5/8, Id1, Id3, BMPR-II and β-actin in PAECs cultured with or without varying 
concentrations of BMP9, BMP4 and BMP6 ligand for 2 hours. Representative of 3 
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experiments. (g) Expression of BMPR2 in PAECs with or without treatment with 10 ng/mL 
BMP9 for 24 hours (n=3; Student’s t test). (h) Representative agarose gels for products from 
chromatin immunoprecipitation on lysates from HMEC-1 cells (top) without treatment, 
(middle) 72 hours after siRNA knockdown of SMAD1 or (bottom) following a 24 hour 
treatment with 1 ng/mL BMP9. (i) Luciferase activity in HMEC-1 lysates transfected with a 
luciferase reporter construct with or without an upstream 5kb portion of the BMPR2 
promoter with or without mutation of the putative Smad binding region. Cells bearing the 
reporter construct were treated with 10 ng/mL BMP9 for 24 hours (n=3; 1-way ANOVA, 
Tukey’s post test). ***P<0.001, **P<0.01, *P<0.05. Mean +/− SEM.
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Figure 2. BMP9 prevents apoptosis in human PAECs via BMPR-II
Representative immunoblots and densitometric analysis for (a) phosphorylated JNK (n=4) 
and (b) cleaved caspase 3 (n=3) in human PAECs cultured with or without BMP9 (5 ng/mL) 
for 16 hours prior to an apoptotic stimulus with TNFα (10 ng/mL) and cyclohexamide (20 
μg/mL) (1-way ANOVA, Tukey’s post test). (c) Representative flow cytometry plots of 
human PAECs stained with Annexin-V and propidium iodide (PI) with or without BMP9 
pre-treatment and apoptotic stimulus. (d) Quantification of apoptotic (Annexin-V+/PI−) 
PAECs (n=5); 1-way ANOVA, Tukey’s post test). (e) Validation of siRNA knockdown in 
PAECs by immunoblotting for BMPR-II following treatment with either Dharmafect 1 
transfection reagent (DH1), siRNA for BMPR2 (siBMPR2) or a pooled siRNA control 
(siCP). (f) Cytometric quantification of apoptosis by staining for Annexin-V and PI in 
PAECs treated with DH1 alone, siBMPR2 or siCP and cultured with or without BMP9 pre-
treatment and apoptotic stimulus (n=6 for DH1 and siBMPR-II, n=5 for siCP; 1-way 
ANOVA for each siRNA group, Tukey’s post test). (g) Representative immunoblot and 
densitometric analysis of cleaved caspase-3 in PAECs following siRNA transfection with or 
without BMP9 pre-treatment and apoptotic stimulus. (n=3; 1-way ANOVA for each siRNA 
group, Tukey’s post test). All blots were re-probed for α-tubulin as a loading control. 
***P<0.001, **P<0.01, * P<0.05. Mean +/− SEM.
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Figure 3. BMP9 prevents apoptosis and promotes monolayer integrity in BOECs with and 
without BMPR-II mutations
(a) Quantification of apoptotic (Annexin-V+/PI−) control (n=5 individuals) and BMPR2 
mutation-bearing BOECs (n=6 individuals) after culture with or without BMP9 (5 ng/mL) 
for 16 hours prior to the addition of TNFα (10 ng/mL) and cyclohexamide (20 μg/mL) for 6 
hours. (b–c) Immunoblotting for (b) phosphorylated JNK and (c) cleaved caspase-3 in 
control and BMPR2 mutation-bearing BOECs with or without BMP9 pre-treatment and 
apoptotic stimulus. Representative of five immunoblots. All blots were re-probed for α-
tubulin as a loading control. (d–f) Permeability of (d) control or (e) BMPR2 mutation-
bearing BOEC monolayers to HRP, assessed as a measure of colorimetric absorbance after 
incubation periods ranging from 30 minutes to 2 hours with or without BMP9 (20 ng/mL) 
and/or LPS (400 ng/mL) (f) Quantification of monolayer permeability at 2 hours post-LPS. 
(n=4 individuals per group). AU: Arbitraty units. ***P<0.001, **P<0.01, *P<0.05, 1-way 
ANOVA, repeated measures Tukey’s post test for Control or BMPR2 Mutation BOECs; 
###P<0.001, ##P<0.01, 1-way ANOVA, Tukey’s post test for all groups. Mean +/− SEM. 
(g) Representative immunofluorescence images of PAECs stained for VE-cadherin 
following 24 hour culture with or without BMP9 (10 ng/mL) and/or LPS (400 ng/mL). Scale 
bars 10 μm.
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Figure 4. Pulmonary hypertension in Bmpr2+/R899X knock-in mice is reversed by BMP9
(a) Assessment of right ventricular systolic pressure (RVSP) in 6-month-old, naive 
Bmpr2+/R899X mice (n=21, 11 male, 10 female) and WT littermate controls (n=23, 13 male, 
10 female) or with 4 weeks of BMP9 treatment (75 ng/day, i.p., n=10 (9 male, 1 female) for 
WT and n=11 (9 male, 2 female) for Bmpr2+/R899X; 1-way ANOVA, Tukey’s post test). (b) 
Right ventricular hypertrophy (Fulton index, ratio of RV weight over LV and septal weight) 
in the same animals as a (not significant). (c) Quantitative assessment of pulmonary arterial 
muscularization in the same groups as a. Displayed as a non-, partially- and fully-
muscularized arteries as a percentage of total alveolar wall and duct arteries (n=12 (6 male, 
6 female) for naïve WT and Bmpr2+/R899X mice; with BMP9 treatment n=3 (2 male, 1 
female) for WT and n=5 (3 male, 2 female) for Bmpr2+/R899X; 1-way ANOVA, Tukey’s 
post test). (d) Representative images of immunohistochemical staining for smooth muscle α-
actin in lung sections from WT and Bmpr2+/R899X mice with or without BMP9 treatment. (e) 
Assessment of RVSP and (f) RV hypertrophy in male 6 month-old WT (n=16), Smad1+/− 
(n=9), Bmpr2+/R899X (n=10) and compound Bmpr2+/R899X/Smad1+/− heterozygotes (n=10; 
1-way ANOVA, Tukey’s post test). (g) Quantification of monolayer permeability at 2 hours 
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post-LPS. (n=3; 1-way ANOVA, repeated measures Tukey’s post test for WT or 
Bmpr2+/R899X cells; #P<0.05, 1-way ANOVA, Tukey’s post test for all groups). AU: 
Arbitrary units. (h) Images of lungs isolated from mice injected with 2 mg/kg LPS or 
vehicle and either 36.79 ng/25g BMP9 or vehicle (all i.p.) 22 hours prior to the i.p. injection 
of Evans blue dye, which was delivered 2 hours prior to sacrifice. (i) Quantitative 
assessment of extravascular Evans blue dye in the lungs of the mice described in h (Control: 
n=7 (5 male, 2 female) for WT, n=9 (4 male, 5 female) for Bmpr2+/R899X; LPS: n=8 (5 
male, 3 female) for WT, n=10 (6 male, 4 female) for Bmpr2+/R899X; LPS + BMP9: n=8 (4 
male, 4 female) for WT, n=9 (5 male, 4 female) for Bmpr2+/R899X; 1-way ANOVA, Tukey’s 
post test for WT or Bmpr2+/R899X mice; #P<0.05, 1-way ANOVA, Tukey’s post test for all 
groups). ***P<0.001, **P<0.01, *P<0.05. Mean +/− SEM.
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Figure 5. BMP9 reverses established monocrotaline-induced pulmonary hypertension and 
prevents endothelial cell apoptosis in rats
(a) Assessment of right ventricular systolic pressure (RVSP) and (b) RV hypertrophy 
(Fulton index) in rats on a prevention protocol given vehicle (n=6) or monocrotaline (60 
mg/kg, i.p.) and treated with BMP9 (n=7, 600 ng/day, i.p.) or vehicle (n=8) from days 0 to 
21 post-MCT (1-way ANOVA, Tukey’s post test). (c) Quantitative assessment of pulmonary 
arterial muscularization in control rats or rats given monocrotaline, followed by daily 
injections with saline or BMP9 in a prevention (days 0–21 post-MCT) or reversal (days 21–
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35 post-MCT) protocol. Displayed as non-, partially- and fully-muscularized arteries as a 
percentage of total alveolar wall and duct arteries (n=5 for prevention, n=6 for reversal; 1-
way ANOVA, Tukey’s post test for fully muscularized vessels). (d) Immunohistochemical 
staining for smooth muscle α-actin in lung sections from the rats as described in c. Scale 
bars 100 μm. (e) Assessment of right ventricular systolic pressure (RVSP) and (f) RV 
hypertrophy (Fulton index) in rats on a reversal protocol given vehicle (n=4) or 
monocrotaline (40 mg/kg, i.p.) and treated with BMP9 (n=10, 600 ng/day) or vehicle (n=9) 
from days 21 to 35 post-MCT (t test on 35 day groups treated with saline or BMP9). (g) 
Representative images of immunohistochemical staining for von Willebrand Factor (upper) 
and cleaved caspase-3 (lower) in lung sections from rats given vehicle control or 
monocrotaline (60 mg/kg, i.p.), treated with BMP9 (600 ng/day, i.p.) or saline from day 0 
and sacrificed on day 5 post-MCT. Scale bars 50 μm. (h) Quantification of cleaved 
caspase-3 positive endothelial cells in lung sections from the groups described in a, b and g 
and sacrificed on days 2, 5 or 21 post-MCT (n=11 for Control, n=6 for days 2 and 5 post-
MCT, n=5 for day 21 post-MCT; 1-way ANOVA, Tukey’s post test). ***P<0.001, 
**P<0.01, *P<0.05. Mean +/− SEM.
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Figure 6. BMP9 reverses established pulmonary hypertension in rats in response to treatment 
with the VEGF receptor inhibitior SU-5416 in combination with chronic hypoxia
(a) Rats were given vehicle injections and maintained in normoxia (n=4) or challenged with 
SU-5416 (20 mg/kg, i.p.) and 3 weeks hypoxia (10% O2) prior to 5 weeks normoxia and 
assessment at 8 weeks (n=7) or at 11 weeks following daily treatment with saline vehicle 
(n=11) or BMP9 (n=11; 600 ng/day, i.p.). (b) Assessment of right ventricular systolic 
pressure (RVSP) and (c) RV hypertrophy (Fulton index) for the rats described in a (1-way 
ANOVA, Tukey’s post test). (d) Quantification of non-, partially- and fully-muscularized 
arteries as a percentage of total alveolar wall and duct arteries (n=4 for control, n=6 for all 
other groups; 1-way ANOVA, Tukey’s post test for fully muscularized vessels). (e) 
Assessment of pulmonary arterial wall thickness as a percentage of luminal diameter (n=4 
for control, n=6 for all other groups; 1-way ANOVA, Tukey’s post test). (f) Quantification 
of neointimal lesion frequency in the lungs of the rats described in a (n=3 for control, n=6 
for all other groups; 1-way ANOVA, Tukey’s post test). (g) Quantification of cleaved 
caspase-3 positive endothelial cells in lung sections from the groups described in a (n=3 for 
control, n=6 for all other groups; 1-way ANOVA, Tukey’s post test). ***P<0.001, 
**P<0.01, *P<0.05. Mean +/− SEM. (h) Neointima formation in the lungs of the rats 
described in a. Lung sections were stained for smooth muscle α-actin (SMA) or with elastic 
van Gieson (EVG) stain. Scale bar = 50μm.
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